PT UBC Medical Indonesia Tbk (IDX:LABS)

Indonesia · Delayed Price · Currency is IDR

146.00

-2.00 (-1.35%)

Jul 15, 2026, 4:05 PM WIB

1.39% (1Y)

Market Cap	584.60B +8.0%
Revenue (ttm)	205.85B +35.1%
Net Income	12.07B +211.6%
EPS	3.06 +211.6%
Shares Out	3.95B
PE Ratio	48.44
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	823,200
Open	148.00
Previous Close	148.00
Day's Range	145.00 - 149.00
52-Week Range	120.00 - 260.00
Beta	-0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About IDX:LABS

PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoschola... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2014

Employees 54

Stock Exchange Indonesia Stock Exchange

Ticker Symbol LABS

Full Company Profile

Financial Performance

In 2025, IDX:LABS's revenue was 199.30 billion, an increase of 34.99% compared to the previous year's 147.64 billion. Earnings were 13.51 billion, an increase of 357.50%.

Financial Statements